Roivant Sciences (ROIV) Return on Capital Employed (2021 - 2025)
Roivant Sciences (ROIV) posted Return on Capital Employed of 47.91% for Q4 2025, down 42.58% on a QoQ basis from 33.6% in Q3 2025, and down 11785.0% year-over-year from N/an in Q4 2024.
Roivant Sciences (ROIV) Return on Capital Employed (2021 - 2025) Analysis & Trends
Roivant Sciences' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 47.91% for Q4 2025.
- Quarterly Return on Capital Employed fell 11785.0% year-over-year to 47.91% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 47.91% (down 11785.0% YoY) and the FY2026 annual result came in at 9.93%, up 843.0% from the prior year.
- Return on Capital Employed was 47.91% for Q4 2025 at Roivant Sciences, down from 33.6% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 84.42% in Q4 2023 and bottomed at 117.24% in Q4 2022.
- A 5-year average of 30.2% and a median of 47.91% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed surged 20166 bps — and 2025, when it plunged 11785 bps.
- Roivant Sciences' Return on Capital Employed stood at 78.22% in 2021, then sank by 50 bps to 117.24% in 2022, then jumped by 172 bps to 84.42% in 2023, then decreased by 17 bps to 69.94% in 2024, then plunged by 169 bps to 47.91% in 2025.
- Business Quant data shows ROIV's Return on Capital Employed at 47.91% in Q4 2025, 33.6% in Q3 2025, and 28.26% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -47.91% |
| Sep 30, 2025 | -33.60% |
| Jun 30, 2025 | -28.26% |
| Dec 31, 2024 | 69.94% |
| Sep 30, 2024 | 77.13% |
| Jun 30, 2024 | 66.13% |
| Dec 31, 2023 | 84.42% |
| Sep 30, 2023 | -81.55% |
| Jun 30, 2023 | -78.96% |
| Dec 31, 2022 | -117.24% |
| Sep 30, 2022 | -107.12% |
| Jun 30, 2022 | -97.44% |
| Dec 31, 2021 | -78.22% |
| Sep 30, 2021 | -50.68% |
| Jun 30, 2021 | -29.59% |